Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

297
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
297
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

174
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
174
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

328
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
328
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

207
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
207
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

303
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
303
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

266
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
266

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Closing the Global Action Plan is not Reasonable for the Materiai in My Commentary that States Closing the Gap.

Epilepsy currents·2026
Same author

Amygdala enlargement in pediatric epilepsy: A clinically meaningful finding?

Epilepsy research·2026
Same author

Response: Lenses protecting against photosensitivity violate international driving regulations.

Epilepsia·2026
Same author

Ask a Simple Question, Design an Elegant Study and the Rest is History.

Epilepsy currents·2026
Same author

Biosimilar Therapeutics Substitution: American Academy of Neurology Position Statement.

Neurology. Clinical practice·2026
Same author

Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD.

Neurology·2025

Related Experiment Video

Updated: May 22, 2025

Employing Transcranial Magnetic Stimulation in a Resource Limited Environment to Establish Brain-Behavior Relationships
06:05

Employing Transcranial Magnetic Stimulation in a Resource Limited Environment to Establish Brain-Behavior Relationships

Published on: April 20, 2022

1.8K

Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement.

Benjamin Tolchin1, Gregory L Krauss2, Marianna V Spanaki3

  • 1Department of Neurology, Yale School of Medicine, New Haven, CT.

Neurology
|March 12, 2025
PubMed
Summary

Updated guidelines recommend a minimum 3-month seizure-free interval for driving, with exceptions for provoked seizures or medication adjustments. These recommendations aim to standardize driver licensure for individuals with epilepsy.

More Related Videos

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
09:16

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury

Published on: June 21, 2019

25.5K
A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

2.6K

Related Experiment Videos

Last Updated: May 22, 2025

Employing Transcranial Magnetic Stimulation in a Resource Limited Environment to Establish Brain-Behavior Relationships
06:05

Employing Transcranial Magnetic Stimulation in a Resource Limited Environment to Establish Brain-Behavior Relationships

Published on: April 20, 2022

1.8K
Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
09:16

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury

Published on: June 21, 2019

25.5K
A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

2.6K

Area of Science:

  • Neurology
  • Public Health Policy

Background:

  • Previous position statements on epilepsy and driving were issued in 1994 and 2007.
  • Driver licensure and medical reporting for individuals with seizures require updated guidance.

Purpose of the Study:

  • To update consensus positions on seizures, driver licensure, and medical reporting for individuals with epilepsy.
  • To provide equitable, objective, and evidence-based criteria for driver licensing.

Main Methods:

  • Consensus development by leading professional organizations (American Academy of Neurology, American Epilepsy Society, Epilepsy Foundation of America).
  • Review and revision of existing guidelines on seizure-free intervals and medical reporting.

Main Results:

  • Recommends a minimum 3-month seizure-free interval, with exceptions for provoked seizures or specific medication management scenarios.
  • Advocates for state licensing criteria to be developed by medical advisory boards and regulations, not statutes.
  • Supports allowing but not mandating reporting of high-risk drivers, with legal liability protection for practitioners.

Conclusions:

  • National driving standards and state-specific regulations should be harmonized for clarity and adherence.
  • Individualized assessment by medical advisory boards is crucial for determining driving eligibility.
  • Alternative transportation solutions are essential for individuals with restricted driving privileges.